This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Leukemia Open Access 09 July 2020
-
How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study
Scientific Reports Open Access 22 August 2017
-
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
Blood Cancer Journal Open Access 07 August 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658–1668.
Pardanani A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 22–30.
Geron I, Abrahamson A, Barroga C, Kavalerchik E, Gotlib J, Hood J et al. Selective inhibition of JAK2 driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008 (in press).
Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008 (in press).
Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135: 683–687.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosures
John Hood is an employee and shareholder of TargeGen Inc. This work was supported by a research grant from TargeGen Inc. and from the Myeloproliferative Disorders Foundation, Chicago, IL, USA.
Rights and permissions
About this article
Cite this article
Lasho, T., Tefferi, A., Hood, J. et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 22, 1790–1792 (2008). https://doi.org/10.1038/leu.2008.56
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.56
This article is cited by
-
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Leukemia (2021)
-
How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study
Scientific Reports (2017)
-
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
Blood Cancer Journal (2015)
-
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy
Oncogene (2015)
-
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
Biomarker Research (2013)